Chemoprevention of gastrointestinal cancer

British Journal of Surgery

Volumn 95, Issue 6, 2008, Pages 674-676

  Dunn, L J ^a   Jankowski, J ^b,c  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; CALCIUM CARBONATE; CELECOXIB; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; PROTON PUMP INHIBITOR; SELENIUM; SULINDAC; URSODEOXYCHOLIC ACID; CYCLOOXYGENASE 2 INHIBITOR;

ADENOMATOUS POLYP; BARRETT ESOPHAGUS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM ADENOMA; SHORT SURVEY; SIGMOIDOSCOPY; STOMACH CANCER; ARTICLE; GASTROINTESTINAL TUMOR; METHODOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMOPREVENTION; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL NEOPLASMS; HUMANS;

EID: 44249087872     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6201     Document Type: Short Survey

References (10)

1. Jankowski JA, Hawk ET. A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 101-111.
2. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890.
3. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 2007; 146: 365-375.
4. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-1316.
5. Corley D, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56.
6. Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007; 99: 545-557.
7. Baron JA, Beach M, MandelJS, van Stolk RU, Haile RW, Sandler RS et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999; 340: 101-107.
8. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000; 6: 1024-1028.
9. Jankowski J, Moayyedi P. Re: cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 2004; 96: 885-887.
10. Das D, Ishaq S, Harrison R, Kosuri K, Harper E, de Caestecker J et al. Management of Barrett's esophagus in die UK: overtreated and underbiopsied but improved by the introduction of a National Randomized Trial. Am J Gastroenterol 2008 (in press).